MedTrace Logo

A Study of Revumenib and Mezigdomide in People With Leukemia

NCT07356154 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-01-21

No results posted yet for this study

Summary

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

Conditions

Interventions

DRUG

Revumenib

Revumenib is a novel menin inhibitor

DRUG

Mezigdomide

Mezigdomide (CC-92480) is an investigational CELMoD.

Sponsors & Collaborators

Principal Investigators

  • Eytan Stein, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-16
Primary Completion
2029-01-16
Completion
2029-01-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07356154 on ClinicalTrials.gov